ID   Hep-G2 B-1
SY   B-1
DR   Wikidata; Q54882780
RX   PubMed=29481805;
CC   Population: Caucasian.
CC   Characteristics: Contains 2 head to tails stably integrated HBV of the A-genotype.
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Transfected with: UniProtKB; P00557; E.coli hygromycin-B 4-O-kinase (hph).
CC   Derived from sampling site: Liver.
DI   NCIt; C3728; Hepatoblastoma
DI   ORDO; Orphanet_449; Hepatoblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_0027 ! Hep-G2
SX   Male
AG   15Y
CA   Cancer cell line
DT   Created: 14-05-18; Last updated: 20-05-21; Version: 8
RX   PubMed=29481805; DOI=10.1016/j.bbrc.2018.02.175;
RA   Ogura N., Ogawa K., Watashi K., Ito T., Wakita T.;
RT   "Novel stable HBV producing cell line systems for expression and
RT   screening antiviral inhibitor of hepatitis B virus in human hepatoma
RT   cell line.";
RL   Biochem. Biophys. Res. Commun. 498:64-71(2018).